Andrew Geall

Company: Replicate Bioscience

Job title: Co-Founder & Chief Development Officer

Seminars:

LNP & Polymer Delivery of Self-Replicating RNA: Unlocking the Potential of Low Dose RNA Vaccines & Gene Therapy 9:30 am

LNP delivery of self-replicating RNA rabies vaccine elicits protective immunity in a majority of healthy participants down to 0.1 microgram (mcg) doses in a prime-boost schedule There were no severe adverse events reported across all doses tested (0.1, 1 and 10 mcg), which supports a massive increase in the therapeutic index achievable with RNA technology…Read more

day: Day 2